Giaquinto AN, Sung H, Miller KD, Kramer JL, Newman LA, Minihan A, Jemal A, Siegel RL (2022) Breast cancer statistics, 2022. CA Cancer J Clin 72(6):524–541. https://doi.org/10.3322/caac.21754

Article  PubMed  Google Scholar 

Hackshaw MD, Danysh HE, Henderson M, Wang E, Tu N, Islam Z, Ladner A, Ritchey ME, Salas M (2021) Prognostic factors of brain metastasis and survival among HER2-positive metastatic breast cancer patients: a systematic literature review. BMC Cancer 21(1):967. https://doi.org/10.1186/s12885-021-08708-5

Article  PubMed  PubMed Central  Google Scholar 

Yeeravalli R, Das A (2021) Molecular mediators of breast cancer metastasis. Hematol Oncol Stem Cell Ther 14(4):275–289. https://doi.org/10.1016/j.hemonc.2021.02.002

Article  CAS  PubMed  Google Scholar 

Singh K, Saxena S, Khosla AA, McDermott MW, Kotecha RR, Ahluwalia MS (2022) Update on the management of brain metastasis. Neurotherapeutics 19(6):1772–1781. https://doi.org/10.1007/s13311-022-01312-w

Article  PubMed  PubMed Central  Google Scholar 

Watase C, Shiino S, Shimoi T, Noguchi E, Kaneda T, Yamamoto Y, Yonemori K, Takayama S, Suto A (2021) Breast cancer brain metastasis-overview of disease state, treatment options and future perspectives. Cancers (Basel) 13(5):1078. https://doi.org/10.3390/cancers13051078

Article  CAS  PubMed  Google Scholar 

Hall WA, Djalilian HR, Nussbaum ES, Cho KH (2000) Long-term survival with metastatic cancer to the brain. Med Oncol 17:279–286

Article  CAS  PubMed  Google Scholar 

Andrews DW, Scott CB, Sperduto PW et al (2004) Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 363:1665–1672

Article  PubMed  Google Scholar 

Kelly PJ, Lin NU, Claus EB et al (2012) Salvage stereotactic radiosurgery for breast cancer brain metastases: outcomes and prognostic factors. Cancer 118:2014–2016

Article  PubMed  Google Scholar 

Hadjipanteli A, Doolan P, Kyriacou E, Constantinidou A (2020) Breast cancer brain metastasis: the potential role of MRI beyond current clinical applications. Cancer Manag Res 12:9953–9964. https://doi.org/10.2147/CMAR.S252801

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ivanova M, Porta FM, Giugliano F, Frascarelli C, Sajjadi E, Venetis K, Cursano G, Mazzarol G, Guerini-Rocco E, Curigliano G, Criscitiello C, Fusco N (2023) Breast cancer with brain metastasis: molecular insights and clinical management. Genes (Basel) 14(6):1160. https://doi.org/10.3390/genes14061160

Article  CAS  PubMed  Google Scholar 

Kuksis M, Gao Y, Tran W, Hoey C, Kiss A, Komorowski AS, Dhaliwal AJ, Sahgal A, Das S, Chan KK, Jerzak KJ (2021) The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis. Neuro Oncol 23(6):894–904. https://doi.org/10.1093/neuonc/noaa285

Article  PubMed  Google Scholar 

Nakhjavani M, Samarasinghe RM, Shigdar S (2022) Triple-negative breast cancer brain metastasis: an update on druggable targets, current clinical trials, and future treatment options. Drug Discov Today 27(5):1298–1314. https://doi.org/10.1016/j.drudis.2022.01.010

Article  PubMed  Google Scholar 

Sun H, Xu J, Dai S, Ma Y, Sun T (2023) Breast cancer brain metastasis: current evidence and future directions. Cancer Med 12(2):1007–1024. https://doi.org/10.1002/cam4.5021

Garcia-Alvarez A, Papakonstantinou A, Oliveira M (2021) Brain metastases in HER2-positive breast cancer: current and novel treatment strategies. Cancers (Basel) 13(12):2927. https://doi.org/10.3390/cancers13122927

Article  CAS  PubMed  Google Scholar 

Tomita Y, Kurozumi K, Fujii K, Shimazu Y, Date I (2020) Neurosurgery for brain metastasis from breast cancer. Transl Cancer Res 9(8):5063–5076. https://doi.org/10.21037/tcr.2020.03.68

Vogelbaum MA, Brown PD, Messersmith H, Brastianos PK, Burri S, Cahill D, Dunn IF, Gaspar LE, Gatson NTN, Gondi V, Jordan JT, Lassman AB, Maues J, Mohile N, Redjal N, Stevens G, Sulman E, van den Bent M, Wallace HJ, Weinberg JS, Zadeh G, Schiff D (2022) Treatment for brain metastases: ASCO-SNO-ASTRO guideline. J Clin Oncol 40(5):492-516. https://doi.org/10.1200/JCO.21.02314. Erratum in: J Clin Oncol. 2022 Apr 20;40(12):1392

Gazzeri R, Nalavenkata S, Teo C (2014) Minimally invasive key-hole approach for the surgical treatment of single and multiple brain metastases. Clin Neurol Neurosurg 123:117–126. https://doi.org/10.1016/j.clineuro.2014.05.010

Article  PubMed  Google Scholar 

Gao C, Wang F, Suki D, Strom E, Li J, Sawaya R, Hsu L, Raghavendra A, Tripathy D, Ibrahim NK (2021) Effects of systemic therapy and local therapy on outcomes of 873 breast cancer patients with metastatic breast cancer to brain: MD Anderson Cancer Center experience. Int J Cancer 148(4):961–970. https://doi.org/10.1002/ijc.33243

Article  CAS  PubMed  Google Scholar 

Corti C, Antonarelli G, Criscitiello C, Lin NU, Carey LA, Cortés J, Poortmans P, Curigliano G (2022) Targeting brain metastases in breast cancer. Cancer Treat Rev 103:102324. https://doi.org/10.1016/j.ctrv.2021.102324

Article  CAS  PubMed  Google Scholar 

Bailleux C, Eberst L, Bachelot T (2021) Treatment strategies for breast cancer brain metastases. Br J Cancer 124(1):142–155. https://doi.org/10.1038/s41416-020-01175-y

Article  PubMed  Google Scholar 

Kayama T, Sato S, Sakurada K, Mizusawa J, Nishikawa R, Narita Y, Sumi M, Miyakita Y, Kumabe T, Sonoda Y, Arakawa Y, Miyamoto S, Beppu T, Sugiyama K, Nakamura H, Nagane M, Nakasu Y, Hashimoto N, Terasaki M, Matsumura A, Ishikawa E, Wakabayashi T, Iwadate Y, Ohue S, Kobayashi H, Kinoshita M, Asano K, Mukasa A, Tanaka K, Asai A, Nakamura H, Abe T, Muragaki Y, Iwasaki K, Aoki T, Watanabe T, Sasaki H, Izumoto S, Mizoguchi M, Matsuo T, Takeshima H, Hayashi M, Jokura H, Mizowaki T, Shimizu E, Shirato H, Tago M, Katayama H, Fukuda H, Shibui S; Japan Clinical Oncology Group (2018) Effects of Surgery With Salvage Stereotactic Radiosurgery Versus Surgery With Whole-Brain Radiation Therapy in Patients With One to Four Brain Metastases (JCOG0504): A Phase III, Noninferiority, Randomized Controlled Trial. J Clin Oncol JCO2018786186. https://doi.org/10.1200/JCO.2018.78.6186

Brown PD, Ballman KV, Cerhan JH, Anderson SK, Carrero XW, Whitton AC, Greenspoon J, Parney IF, Laack NNI, Ashman JB, Bahary JP, Hadjipanayis CG, Urbanic JJ, Barker FG 2nd, Farace E, Khuntia D, Giannini C, Buckner JC, Galanis E, Roberge D (2017) Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol 18(8):1049–1060. https://doi.org/10.1016/S1470-2045(17)30441-2

Article  PubMed  PubMed Central  Google Scholar 

Zimmer AS, Van Swearingen AED, Anders CK (2022) HER2-positive breast cancer brain metastasis: a new and exciting landscape. Cancer Rep (Hoboken) 5(4):e1274. https://doi.org/10.1002/cnr2.1274

Article  PubMed  Google Scholar 

Freedman RA, Gelman RS, Anders CK, Melisko ME, Parsons HA, Cropp AM, Silvestri K, Cotter CM, Componeschi KP, Marte JM, Connolly RM, Moy B, Van Poznak CH, Blackwell KL, Puhalla SL, Jankowitz RC, Smith KL, Ibrahim N, Moynihan TJ, O'Sullivan CC, Nangia J, Niravath P, Tung N, Pohlmann PR, Burns R, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU; Translational Breast Cancer Research Consortium (2019) TBCRC 022: a phase II trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases. J Clin Oncol 37(13):1081–1089. https://doi.org/10.1200/JCO.18.01511

Won KA, Spruck C (2020) Triple-negative breast cancer therapy: Current and future perspectives (Review). Int J Oncol 57(6):1245–1261. https://doi.org/10.3892/ijo.2020.5135

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lyons TG (2019) Targeted therapies for triple-negative breast cancer. Curr Treat Options Oncol 20(11):82. https://doi.org/10.1007/s11864-019-0682-x

Article  PubMed  Google Scholar 

Kim DS, Camacho CV, Kraus WL (2021) Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance. Exp Mol Med 53(1):42–51. https://doi.org/10.1038/s12276-021-00557-3

Article  CAS  PubMed  PubMed Central  Google Scholar 

Klaas E, Sung E, Azizi E, Martinez M, Barpujari A, Roberts J, Lucke-Wold B (2023) Advanced breast cancer metastasized in the brain: treatment standards and innovations. J Cancer Metastasis Treat 9:23. https://doi.org/10.20517/2394-4722.2022.125

Deng J, Chernikova SB, Wang Y, Rodriguez ML, Andersen SJ, Umeh-Garcia MC, Godfrey BO, Ahmadian SS, Fischer WN, Koller KJ, Jandeleit B, Ringold GM, Gephart MH (2021) A novel brain-permeant chemotherapeutic agent for the treatment of brain metastasis in triple-negative breast cancer. Mol Cancer Ther 20(11):2110–2116. https://doi.org/10.1158/1535-7163.MCT-21-0140

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ngamcherdtrakul W, Bejan DS, Cruz-Muñoz W, Reda M, Zaidan HY, Siriwon N, Marshall S, Wang R, Nelson MA, Rehwaldt JPC, Gray JW, Hynynen K, Yantasee W (2022) Targeted nanoparticle for Co-delivery of HER2 siRNA and a taxane to mirror the standard treatment of HER2+ breast cancer: efficacy in breast tumor and brain metastasis. Small 18(11):e2107550. https://doi.org/10.1002/smll.202107550

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kulukian A, Lee P, Taylor J, Rosler R, de Vries P, Watson D, Forero-Torres A, Peterson S (2020) Preclinical activity of HER2-selective tyrosine kinase inhibitor tucatinib as a single agent or in combination with trastuzumab or docetaxel in solid tumor models. Mol Cancer Ther 19(4):976–987. https://doi.org/10.1158/1535-7163.MCT-19-0873

Article  CAS  PubMed  Google Scholar 

Mercatali L, Vanni S, Miserocchi G, Liverani C, Spadazzi C, Cocchi C, Calabrese C, Gurrieri L, Fausti V, Riva N, Genovese D, Lucarelli E, Focarete ML, Ibrahim T, Calabrò L, De Vita A (2022) The emerging role of cancer nanotechnology in the panorama of sarcoma. Front BioengBiotechnol 10:953555. https://doi.org/10.3389/fbioe.2022.953555

Article  Google Scholar 

Valencia-Lazcano AA, Hassan D, Pourmadadi M, Shamsabadipour A, Behzadmehr R, Rahdar A, Medina DI, Díez-Pascual AM (2023) 5-Fluorouracil nano-delivery systems as a cutting-edge for cancer therapy. Eur J Med Chem 246:114995. https://doi.org/10.1016/j.ejmech.2022.114995

Article  CAS  PubMed  Google Scholar